Recruiting
Phase 2
Phase 3

Atezolizumab with Chemotherapy

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05058651

Conditions

Advanced Extrapulmonary Neuroendocrine Carcinoma

Metastatic Extrapulmonary Neuroendocrine Carcinoma

Recurrent Extrapulmonary Neuroendocrine Carcinoma

Unresectable Extrapulmonary Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atezolizumab

Biospecimen Collection

Carboplatin

Cisplatin

Computed Tomography

Study Details

Brief summary:

This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.

Conditions

Advanced Extrapulmonary Neuroendocrine Carcinoma

Metastatic Extrapulmonary Neuroendocrine Carcinoma

Recurrent Extrapulmonary Neuroendocrine Carcinoma

Unresectable Extrapulmonary Neuroendocrine Carcinoma

Study ID

NCT05058651

Start date

Jun 28, 2022

Status verified date

Sep, 2026

Completion date

Oct 1, 2028

Anticipated

Primary completion date

Oct 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must have histologically-confirmed (local site pathological confirmation sufficient) extrapulmonary poorly differentiated, neuroendocrine carcinoma (NEC)
  • Participants must have disease that is unresectable or metastatic and not eligible for definitive therapy as deemed per the treating investigator
  • Participants must have radiologically evaluable disease, measurable or non-measurable, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. All measurable and nonmeasurable lesions must be assessed by CT scan with IV contrast of the chest/abdomen/and pelvis (or CT chest without contrast and MRI abdomen/pelvis with gadolinium contrast, if contraindication to CT iodinated contrast) within 28 days prior to registration. While may be used for routine clinical evaluation, PET scans and bone scans alone are not acceptable for disease assessment while participating in this study. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form
  • Participants must have brain MRI (or CT head with contrast if there is contraindication to MRI brain) if clinically indicated within 28 days prior to registration. Note: Brain imaging is not required in participants without known and/or clinical concern for brain metastases. Participants with asymptomatic central nervous system (CNS) metastases are eligible if one or more of the following apply:

  • Participants who have received treatment for brain metastases must have:

  • No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
  • Discontinued all corticosteroids at least 14 days prior to registration
  • Participants with treatment-naive brain lesions must have:

  • No lesion measuring > 2.0 cm in size in any axis
  • MRI brain or CT head with contrast (if there is contraindication to MRI brain) demonstrating no evidence for mass effect, edema, or other impending neurological compromise within 28 days prior to registration
  • No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
  • No need for > 2 mg of dexamethasone (or equivalent of > 10 mg prednisone) per day at time of registration
  • Participants must not have symptomatic central nervous system (CNS) metastases
  • Participants must not have known or suspected leptomeningeal disease
  • Participants with prior history of non-metastatic (localized/locally advanced disease) extrapulmonary poorly differentiated NEC may have had prior platinum-based therapy +/- radiation +/- surgery provided that all therapy was completed >= 6 months prior to registration
  • Participants must discontinue denosumab prior to study registration and plan to replace with a bisphosphonate while on the study
  • Participants must not have had prior treatment for advanced or metastatic NEC EXCEPT one cycle of platinum (carboplatin/cisplatin) + etoposide is allowed prior to registration. Other chemotherapy regimens are not allowed. For participants with prostate or urothelial NEC, prior chemotherapy for the non-NEC component (e.g. adenocarcinoma or urothelial) is allowed as long as such therapy was completed >= 24 weeks prior to registration and participants have recovered from all prior toxicities to =< grade 1.
  • Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, antiPD-L2, CD137 agonists, anti-CTLA-4 agent, or any other immune checkpoint inhibitors for any neuroendocrine neoplasm. Immune checkpoint inhibitors given for other cancer indications are allowed provided last therapy was given at least 12 months prior to study registration
  • Participants must not have received treatment with systemic immunostimulatory agents including, but not limited to, interferon and interleukin2 \[IL-2\] within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to registration
  • Participants must not have had history of known severe allergy, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies, including to Chinese hamster ovary cell products or to any component of the atezolizumab formulation, cisplatin, carboplatin, or etoposide
  • Participants must not be on active systemic therapy for another cancer with the exception of hormonal therapy including androgen deprivation therapy (e.g., gonadotropin-releasing hormone \[GnRH\] agonists or antagonists), which can be continued while participants are receiving protocol therapy. Use of enzalutamide or apalutamide is permitted after completion of chemotherapy and must be held during chemotherapy for participants receiving prior to enrollment. Use of darolutamide is permitted during chemotherapy. Glucocorticoid-containing regimens, including abiraterone, are not permitted.
  • Participants must be >= 18 years of age
  • Participants must have a Zubrod performance status of =< 2 within 28 days prior to registration
  • Participants must have a complete medical history and physical exam within 28 days prior to registration
  • Absolute neutrophil count (ANC) >= 1.5 x 10\^9 /L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • Hemoglobin >= 9.0 g/dl (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • Platelet count >= 100 x 10\^9/L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (ULN) (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • Serum total bilirubin =< 1.5 x ULN (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • Adequate renal function as defined by any 1 of the following: 1) Measured creatinine clearance (CL) > 50 mL/min OR 2) Calculated creatinine CL > 50 mL/min by the Cockcroft-Gault formula OR by 24-hour urine collection for determination of creatinine clearance (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
  • Participants must not have uncontrolled or symptomatic hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN) within 14 days prior to registration. Participants who have asymptomatic hypercalcemia are eligible provided that medical therapy to treat the hypercalcemia is planned
  • Participants must not have a diagnosis of immunodeficiency nor be receiving systemic steroid therapy (equivalent of > 20 mg of hydrocortisone per day) or any other form of immunosuppressive therapy within 14 days prior to registration
  • Participants must not have active or history of autoimmune disease or immune deficiency, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis with the following exceptions:

  • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study
  • Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study
  • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

  • Rash must cover < 10% of body surface area
  • Disease is well controlled at baseline and requires only low-potency topical corticosteroids
  • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
  • Participants must not have history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. NOTE: History of radiation pneumonitis in the radiation field (fibrosis) is permitted
  • Participants must not have significant cardiovascular disease, such as New York Heart Association class II or greater cardiac disease, myocardial infarction within 3 months prior to registration, unstable arrythmias, or unstable angina
  • Participants must not have had a major surgical procedure other than for diagnosis within 28 days prior to registration. Participant must not plan to receive a major surgical procedure during the course of protocol treatment. NOTE: Patient port placement is not considered a major surgery
  • Participants must not have severe infections (i.e., Common Terminology Criteria for Adverse Events \[CTCAE\] grade >= 2) at time of registration, including but not limited to hospitalization for complications for infection, bacteremia, or severe pneumonia
  • Participants must not have known active tuberculosis
  • Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load, with testing performed as clinically indicated
  • Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV viral load, with testing performed as clinically indicated
  • Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load within 6 months of registration
  • Participants must not have prior allogeneic bone marrow transplantation or solid organ transplant
  • Participants must not have received administration of a live, attenuated vaccine (e.g., FluMist \[registered trademark\]) within 28 days prior to initiation of study treatment, during treatment with atezolizumab, and not plan to receive for 5 months after the last dose of atezolizumab
  • Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method (with details provided as a part of the consent process) during the treatment period and for 5 months after the final dose of atezolizumab. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
  • Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System
  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Study Design

Enrollment

189 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm I (atezolizumab, platinum drug, etoposide)

During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.

experimental: Arm II (atezolizumab, platinum drug, etoposide, observation)

During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study. (CLOSED TO ACCRUAL 7/9/26)

active comparator: Arm III (platinum drug, etoposide, observation)

During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.

Interventions

Atezolizumab

Given IV

Biospecimen Collection

Undergo blood sample collection

Carboplatin

Given IV

Cisplatin

Given IV

Computed Tomography

Undergo CT scan

Etoposide

Given IV

Magnetic Resonance Imaging

Undergo MRI

Patient Observation

Undergo observation

Primary outcome measure

  • Overall survival [ Time Frame: From date of registration or from date of start of observation/maintenance therapy to date of death due to any cause, assessed up to 5 years ]

Central Contacts and Locations

Locations

Cancer Center at Saint Joseph's

Recruiting

Phoenix, Arizona, United States, 85004

Contacts

Site Public Contact

720-874-1881ResearchInstituteInquiries@CommonSpirit.org

Principal Investigator:

Shahzad Siddique

Mayo Clinic Hospital in Arizona

Recruiting

Phoenix, Arizona, United States, 85054

Contacts

Site Public Contact

855-776-0015

Principal Investigator:

Jacob Orme

Kaiser Permanente-Anaheim

Recruiting

Anaheim, California, United States, 92806

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Sutter Auburn Faith Hospital

Recruiting

Auburn, California, United States, 95602

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Sutter Cancer Centers Radiation Oncology Services-Auburn

Recruiting

Auburn, California, United States, 95603

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Kaiser Permanente-Baldwin Park

Recruiting

Baldwin Park, California, United States, 91706

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Kaiser Permanente-Bellflower

Recruiting

Bellflower, California, United States, 90706

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Alta Bates Summit Medical Center-Herrick Campus

Recruiting

Berkeley, California, United States, 94704

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Recruiting

Cameron Park, California, United States, 95682

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Mercy Cancer Center - Carmichael

Recruiting

Carmichael, California, United States, 95608

Contacts

Site Public Contact

720-874-1881ResearchInstituteInquiries@CommonSpirit.org

Principal Investigator:

Shahzad Siddique

Mercy San Juan Medical Center

Recruiting

Carmichael, California, United States, 95608

Contacts

Site Public Contact

720-874-1881ResearchInstituteInquiries@commonspirit.org

Principal Investigator:

Shahzad Siddique

Mercy Cancer Center - Elk Grove

Recruiting

Elk Grove, California, United States, 95758

Contacts

Site Public Contact

720-874-1881ResearchInstituteInquiries@CommonSpirit.org

Principal Investigator:

Shahzad Siddique

Kaiser Permanente-Fontana

Recruiting

Fontana, California, United States, 92335

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Palo Alto Medical Foundation-Fremont

Recruiting

Fremont, California, United States, 94538

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Kaiser Permanente South Bay

Recruiting

Harbor City, California, United States, 90710

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Kaiser Permanente-Irvine

Recruiting

Irvine, California, United States, 92618

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Kaiser Permanente Los Angeles Medical Center

Recruiting

Los Angeles, California, United States, 90027

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Kaiser Permanente West Los Angeles

Recruiting

Los Angeles, California, United States, 90034

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Memorial Medical Center

Recruiting

Modesto, California, United States, 95355

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Palo Alto Medical Foundation-Camino Division

Recruiting

Mountain View, California, United States, 94040

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Kaiser Permanente-Ontario

Recruiting

Ontario, California, United States, 91761

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Palo Alto Medical Foundation Health Care

Recruiting

Palo Alto, California, United States, 94301

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Kaiser Permanente - Panorama City

Recruiting

Panorama City, California, United States, 91402

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Kaiser Permanente-Riverside

Recruiting

Riverside, California, United States, 92505

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Mercy Cancer Center - Rocklin

Recruiting

Rocklin, California, United States, 95765

Contacts

Site Public Contact

720-874-1881ResearchInstituteInquiries@CommonSpirit.org

Principal Investigator:

Shahzad Siddique

Sutter Cancer Centers Radiation Oncology Services-Roseville

Recruiting

Roseville, California, United States, 95661

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Sutter Roseville Medical Center

Recruiting

Roseville, California, United States, 95661

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Mercy Cancer Center - Sacramento

Recruiting

Sacramento, California, United States, 95816

Contacts

Site Public Contact

720-874-1881ResearchInstituteInquiries@CommonSpirit.org

Principal Investigator:

Shahzad Siddique

Sutter Medical Center Sacramento

Recruiting

Sacramento, California, United States, 95816

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Kaiser Permanente-San Diego Zion

Recruiting

San Diego, California, United States, 92120

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

California Pacific Medical Center-Pacific Campus

Recruiting

San Francisco, California, United States, 94115

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Kaiser Permanente-San Marcos

Recruiting

San Marcos, California, United States, 92078

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

Palo Alto Medical Foundation-Santa Cruz

Recruiting

Santa Cruz, California, United States, 95065

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Sutter Pacific Medical Foundation

Recruiting

Santa Rosa, California, United States, 95403

Contacts

Site Public Contact

415-209-2683clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Palo Alto Medical Foundation-Sunnyvale

Recruiting

Sunnyvale, California, United States, 94086

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Sutter Solano Medical Center/Cancer Center

Recruiting

Vallejo, California, United States, 94589

Contacts

Site Public Contact

clinicalresearch@sutterhealth.org

Principal Investigator:

Kristie A. Bobolis

Woodland Memorial Hospital

Recruiting

Woodland, California, United States, 95695

Contacts

Site Public Contact

720-874-1881ResearchInstituteInquiries@CommonSpirit.org

Principal Investigator:

Shahzad Siddique

Kaiser Permanente-Woodland Hills

Recruiting

Woodland Hills, California, United States, 91367

Contacts

Site Public Contact

800-398-3996clinical.trials@kp.org

Principal Investigator:

Helen H. Moon

AdventHealth Porter

Recruiting

Denver, Colorado, United States, 80210

Contacts

Site Public Contact

research.institute@adventhealth.com

Principal Investigator:

Yousuf A. Gaffar

AdventHealth Littleton

Recruiting

Littleton, Colorado, United States, 80122

Contacts

Site Public Contact

research.institute@adventhealth.com

Principal Investigator:

Yousuf A. Gaffar

AdventHealth Parker

Recruiting

Parker, Colorado, United States, 80138

Contacts

Site Public Contact

research.institute@adventhealth.com

Principal Investigator:

Yousuf A. Gaffar

Smilow Cancer Hospital-Derby Care Center

Recruiting

Derby, Connecticut, United States, 06418

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Smilow Cancer Hospital Care Center-Fairfield

Recruiting

Fairfield, Connecticut, United States, 06824

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Smilow Cancer Hospital Care Center at Greenwich

Recruiting

Greenwich, Connecticut, United States, 06830

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Smilow Cancer Hospital Care Center - Guilford

Recruiting

Guilford, Connecticut, United States, 06437

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Yale University

Recruiting

New Haven, Connecticut, United States, 06520

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Yale-New Haven Hospital North Haven Medical Center

Recruiting

North Haven, Connecticut, United States, 06473

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Smilow Cancer Hospital Care Center at Long Ridge

Recruiting

Stamford, Connecticut, United States, 06902

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Smilow Cancer Hospital-Torrington Care Center

Recruiting

Torrington, Connecticut, United States, 06790

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Smilow Cancer Hospital Care Center-Trumbull

Recruiting

Trumbull, Connecticut, United States, 06611

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Smilow Cancer Hospital-Waterbury Care Center

Recruiting

Waterbury, Connecticut, United States, 06708

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Smilow Cancer Hospital Care Center - Waterford

Recruiting

Waterford, Connecticut, United States, 06385

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Holy Cross Hospital

Recruiting

Fort Lauderdale, Florida, United States, 33308

Contacts

Site Public Contact

eileen.georgi@holy-cross.com

Principal Investigator:

Tareq Al baghdadi

Mayo Clinic in Florida

Recruiting

Jacksonville, Florida, United States, 32224-9980

Contacts

Site Public Contact

855-776-0015

Principal Investigator:

Jacob Orme

Moffitt Cancer Center

Recruiting

Tampa, Florida, United States, 33612

Contacts

Site Public Contact

800-679-0775ClinicalTrials@moffitt.org

Principal Investigator:

Mintallah Haider

Hawaii Cancer Care Inc - Waterfront Plaza

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Site Public Contact

808-524-6115i.webster@hawaiicancercare.com

Principal Investigator:

Elizabeth S. Nakasone

Queen's Cancer Cenrer - POB I

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Site Public Contact

808-532-0315

Principal Investigator:

Elizabeth S. Nakasone

Queen's Medical Center

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Site Public Contact

808-545-8548

Principal Investigator:

Elizabeth S. Nakasone

Straub Clinic and Hospital

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Site Public Contact

808-522-4333

Principal Investigator:

Elizabeth S. Nakasone

University of Hawaii Cancer Center

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Site Public Contact

808-586-2979

Principal Investigator:

Elizabeth S. Nakasone

Queen's Cancer Center - Kuakini

Recruiting

Honolulu, Hawaii, United States, 96817

Contacts

Site Public Contact

808-531-8521

Principal Investigator:

Elizabeth S. Nakasone

Hawaii Cancer Care - Westridge

Recruiting

‘Aiea, Hawaii, United States, 96701

Contacts

Site Public Contact

808-539-2273info@hawaiicancercare.com

Principal Investigator:

Elizabeth S. Nakasone

The Queen's Medical Center - West Oahu

Recruiting

‘Ewa Beach, Hawaii, United States, 96706

Contacts

Site Public Contact

rohta@queens.org

Principal Investigator:

Elizabeth S. Nakasone

Kootenai Health - Coeur d'Alene

Recruiting

Coeur d'Alene, Idaho, United States, 83814

Contacts

Site Public Contact

406-969-6060mccinfo@mtcancer.org

Principal Investigator:

John M. Schallenkamp

Saint Alphonsus Cancer Care Center-Nampa

Recruiting

Nampa, Idaho, United States, 83687

Contacts

Site Public Contact

406-969-6060mccinfo@mtcancer.org

Principal Investigator:

Tareq Al baghdadi

Kootenai Clinic Cancer Services - Post Falls

Recruiting

Post Falls, Idaho, United States, 83854

Contacts

Site Public Contact

406-969-6060mccinfo@mtcancer.org

Principal Investigator:

John M. Schallenkamp

Kootenai Clinic Cancer Services - Sandpoint

Recruiting

Sandpoint, Idaho, United States, 83864

Contacts

Site Public Contact

406-969-6060mccinfo@mtcancer.org

Principal Investigator:

John M. Schallenkamp

Rush-Copley Medical Center

Recruiting

Aurora, Illinois, United States, 60504

Contacts

Site Public Contact

630-978-6212RCMC_Cancer_Research@rush.edu

Principal Investigator:

Vamsi K. Vasireddy

Centralia Oncology Clinic

Recruiting

Centralia, Illinois, United States, 62801

Contacts

Site Public Contact

217-876-4762morganthaler.jodi@mhsil.com

Principal Investigator:

Bryan A. Faller

Northwestern University

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Site Public Contact

312-695-1301cancer@northwestern.edu

Principal Investigator:

Mary F. Mulcahy

University of Chicago Comprehensive Cancer Center

Recruiting

Chicago, Illinois, United States, 60637

Contacts

Site Public Contact

773-702-8222cancerclinicaltrials@bsd.uchicago.edu

Principal Investigator:

Ardaman Shergill

Carle at The Riverfront

Recruiting

Danville, Illinois, United States, 61832

Contacts

Site Public Contact

800-446-5532Research@Carle.com

Principal Investigator:

Vamsi K. Vasireddy

Cancer Care Specialists of Illinois - Decatur

Recruiting

Decatur, Illinois, United States, 62526

Contacts

Site Public Contact

217-876-4762morganthaler.jodi@mhsil.com

Principal Investigator:

Bryan A. Faller

Decatur Memorial Hospital

Recruiting

Decatur, Illinois, United States, 62526

Contacts

Site Public Contact

217-876-4762morganthaler.jodi@mhsil.com

Principal Investigator:

Bryan A. Faller

Northwestern Medicine Cancer Center Kishwaukee

Recruiting

DeKalb, Illinois, United States, 60115

Contacts

Site Public Contact

630-352-5360Donald.Smith3@nm.org

Principal Investigator:

Mary F. Mulcahy

Carle Physician Group-Effingham

Recruiting

Effingham, Illinois, United States, 62401

Contacts

Site Public Contact

800-446-5532Research@carle.com

Principal Investigator:

Vamsi K. Vasireddy

Crossroads Cancer Center

Recruiting

Effingham, Illinois, United States, 62401

Contacts

Site Public Contact

217-876-4762morganthaler.jodi@mhsil.com

Principal Investigator:

Bryan A. Faller

Northwestern Medicine Cancer Center Delnor

Recruiting

Geneva, Illinois, United States, 60134

Contacts

Site Public Contact

630-352-5360Donald.Smith3@nm.org

Principal Investigator:

Mary F. Mulcahy

Northwestern Medicine Glenview Outpatient Center

Recruiting

Glenview, Illinois, United States, 60026

Contacts

Site Public Contact

312-695-1102

Principal Investigator:

Mary F. Mulcahy

Northwestern Medicine Grayslake Outpatient Center

Recruiting

Grayslake, Illinois, United States, 60030

Contacts

Site Public Contact

312-695-1102

Principal Investigator:

Mary F. Mulcahy

Ingalls Memorial Hospital

Recruiting

Harvey, Illinois, United States, 60426

Contacts

Site Public Contact

708-915-4673clinicaltrials@ingalls.org

Principal Investigator:

James A. Wallace

Northwestern Medicine Lake Forest Hospital

Recruiting

Lake Forest, Illinois, United States, 60045

Contacts

Site Public Contact

cancertrials@northwestern.edu

Principal Investigator:

Mary F. Mulcahy

Carle Physician Group-Mattoon/Charleston

Recruiting

Mattoon, Illinois, United States, 61938

Contacts

Site Public Contact

800-446-5532Research@carle.com

Principal Investigator:

Vamsi K. Vasireddy

SSM Health Good Samaritan

Recruiting

Mount Vernon, Illinois, United States, 62864

Contacts

Site Public Contact

618-899-1894gayla.hall@ssmhealth.com

Principal Investigator:

Jay W. Carlson

UC Comprehensive Cancer Center at Silver Cross

Recruiting

New Lenox, Illinois, United States, 60451

Contacts

Site Public Contact

773-702-8222cancerclinicaltrials@bsd.uchicago.edu

Principal Investigator:

Ardaman Shergill

Carle BroMenn Medical Center

Recruiting

Normal, Illinois, United States, 61761

Contacts

Site Public Contact

800-446-5532Research@Carle.com

Principal Investigator:

Vamsi K. Vasireddy

Carle Cancer Institute Normal

Recruiting

Normal, Illinois, United States, 61761

Contacts

Site Public Contact

800-446-5532Research@Carle.com

Principal Investigator:

Vamsi K. Vasireddy

Cancer Care Center of O'Fallon

Recruiting

O'Fallon, Illinois, United States, 62269

Contacts

Site Public Contact

217-876-4762morganthaler.jodi@mhsil.com

Principal Investigator:

Bryan A. Faller

Northwestern Medicine Orland Park

Recruiting

Orland Park, Illinois, United States, 60462

Contacts

Site Public Contact

nctnprogram_rhlccc@northwestern.edu

Principal Investigator:

Mary F. Mulcahy

University of Chicago Medicine-Orland Park

Recruiting

Orland Park, Illinois, United States, 60462

Contacts

Site Public Contact

773-702-8222cancerclinicaltrials@bsd.uchicago.edu

Principal Investigator:

Ardaman Shergill

UW Health Carbone Cancer Center Rockford

Recruiting

Rockford, Illinois, United States, 61114

Contacts

Site Public Contact

779-696-9378lkline@uwhealth.org

Principal Investigator:

Fahrettin Covut

Southern Illinois University School of Medicine

Recruiting

Springfield, Illinois, United States, 62702

Contacts

Site Public Contact

217-545-7929

Principal Investigator:

Bryan A. Faller

Springfield Clinic

Recruiting

Springfield, Illinois, United States, 62702

Contacts

Site Public Contact

800-444-7541

Principal Investigator:

Bryan A. Faller

Springfield Memorial Hospital

Recruiting

Springfield, Illinois, United States, 62781

Contacts

Site Public Contact

217-528-7541pallante.beth@mhsil.com

Principal Investigator:

Bryan A. Faller

Carle Cancer Center

Recruiting

Urbana, Illinois, United States, 61801

Contacts

Site Public Contact

800-446-5532Research@carle.com

Principal Investigator:

Vamsi K. Vasireddy

Northwestern Medicine Cancer Center Warrenville

Recruiting

Warrenville, Illinois, United States, 60555

Contacts

Site Public Contact

630-352-5360Donald.Smith3@nm.org

Principal Investigator:

Mary F. Mulcahy

Rush-Copley Healthcare Center

Recruiting

Yorkville, Illinois, United States, 60560

Contacts

Site Public Contact

630-978-6212Cancer.Research@rushcopley.com

Principal Investigator:

Vamsi K. Vasireddy

UChicago Medicine Northwest Indiana

Recruiting

Crown Point, Indiana, United States, 46307

Contacts

Site Public Contact

855-702-8222cancerclinicaltrials@bsd.uchicago.edu

Principal Investigator:

Ardaman Shergill

Mary Greeley Medical Center

Recruiting

Ames, Iowa, United States, 50010

Contacts

Site Public Contact

515-956-4132

Principal Investigator:

Joseph J. Merchant

McFarland Clinic - Ames

Recruiting

Ames, Iowa, United States, 50010

Contacts

Site Public Contact

515-239-4734ksoder@mcfarlandclinic.com

Principal Investigator:

Joseph J. Merchant

UI Health Care Mission Cancer and Blood - Ankeny Clinic

Recruiting

Ankeny, Iowa, United States, 50023

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Seema Harichand-Herdt

Saint Anthony Regional Hospital

Recruiting

Carroll, Iowa, United States, 51401

Contacts

Site Public Contact

515-689-7658sbenson@iora.org

Principal Investigator:

Seema Harichand-Herdt

Mercy Cancer Center-West Lakes

Recruiting

Clive, Iowa, United States, 50325

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Richard L. Deming

UI Health Care Mission Cancer and Blood - West Des Moines Clinic

Recruiting

Clive, Iowa, United States, 50325

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Seema Harichand-Herdt

Iowa Methodist Medical Center

Recruiting

Des Moines, Iowa, United States, 50309

Contacts

Site Public Contact

515-241-6727

Principal Investigator:

Seema Harichand-Herdt

UI Health Care Mission Cancer and Blood - Des Moines Clinic

Recruiting

Des Moines, Iowa, United States, 50309

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Seema Harichand-Herdt

Broadlawns Medical Center

Recruiting

Des Moines, Iowa, United States, 50314

Contacts

Site Public Contact

515-282-2200

Principal Investigator:

Seema Harichand-Herdt

Mercy Medical Center - Des Moines

Recruiting

Des Moines, Iowa, United States, 50314

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Richard L. Deming

UI Health Care Mission Cancer and Blood - Laurel Clinic

Recruiting

Des Moines, Iowa, United States, 50314

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Seema Harichand-Herdt

McFarland Clinic - Trinity Cancer Center

Recruiting

Fort Dodge, Iowa, United States, 50501

Contacts

Site Public Contact

515-956-4132

Principal Investigator:

Joseph J. Merchant

McFarland Clinic - Marshalltown

Recruiting

Marshalltown, Iowa, United States, 50158

Contacts

Site Public Contact

515-956-4132

Principal Investigator:

Joseph J. Merchant

UI Health Care Mission Cancer and Blood - Waukee Clinic

Recruiting

Waukee, Iowa, United States, 50263

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Seema Harichand-Herdt

Mercy Medical Center-West Lakes

Recruiting

West Des Moines, Iowa, United States, 50266

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Richard L. Deming

LSU Health Baton Rouge-North Clinic

Recruiting

Baton Rouge, Louisiana, United States, 70805

Contacts

Site Public Contact

225-765-7659research@ololrmc.com

Principal Investigator:

Marshall P. Stagg

Our Lady of the Lake Physician Group

Recruiting

Baton Rouge, Louisiana, United States, 70808

Contacts

Site Public Contact

225-765-7659research@ololrmc.com

Principal Investigator:

Marshall P. Stagg

East Jefferson General Hospital

Recruiting

Metairie, Louisiana, United States, 70006

Contacts

Site Public Contact

504-210-3539emede1@lsuhsc.edu

Principal Investigator:

Tara Castellano

LSU Healthcare Network / Metairie Multi-Specialty Clinic

Recruiting

Metairie, Louisiana, United States, 70006

Contacts

Site Public Contact

504-210-3539emede1@lsuhsc.edu

Principal Investigator:

Tara Castellano

University Medical Center New Orleans

Recruiting

New Orleans, Louisiana, United States, 70112

Contacts

Site Public Contact

504-210-3539emede1@lsuhsc.edu

Principal Investigator:

Tara Castellano

Lahey Clinic

Recruiting

Burlington, Massachusetts, United States, 01805

Contacts

Site Public Contact

781-744-3421lhmc-cancer-clinical-trials@lahey.org

Principal Investigator:

Andrew Piper-Vallillo

Lahey Clinic Peabody

Recruiting

Peabody, Massachusetts, United States, 01960

Contacts

Site Public Contact

781-744-3421lhmc-cancer-clinical-trials@lahey.org

Principal Investigator:

Andrew Piper-Vallillo

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Recruiting

Ann Arbor, Michigan, United States, 48106

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

University of Michigan Rogel Cancer Center

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Site Public Contact

800-865-1125CancerAnswerLine@med.umich.edu

Principal Investigator:

Vaibhav Sahai

Bronson Battle Creek

Recruiting

Battle Creek, Michigan, United States, 49017

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Kathleen Y. Butler

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Recruiting

Brighton, Michigan, United States, 48114

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

Trinity Health Medical Center - Brighton

Recruiting

Brighton, Michigan, United States, 48114

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford Cancer Institute-Downriver

Recruiting

Brownstown, Michigan, United States, 48183

Contacts

Site Public Contact

313-916-3721CTOResearch@hfhs.org

Principal Investigator:

Haythem Y. Ali

Trinity Health IHA Medical Group Hematology Oncology - Canton

Recruiting

Canton, Michigan, United States, 48188

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

Trinity Health Medical Center - Canton

Recruiting

Canton, Michigan, United States, 48188

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

Chelsea Hospital

Recruiting

Chelsea, Michigan, United States, 48118

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Recruiting

Chelsea, Michigan, United States, 48118

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford Macomb Hospital-Clinton Township

Recruiting

Clinton Township, Michigan, United States, 48038

Contacts

Site Public Contact

313-916-3721CTOResearch@hfhs.org

Principal Investigator:

Haythem Y. Ali

Corewell Health Dearborn Hospital

Recruiting

Dearborn, Michigan, United States, 48124

Contacts

Site Public Contact

248-551-7695

Principal Investigator:

Andrew A. Muskovitz

Henry Ford Medical Center-Fairlane

Recruiting

Dearborn, Michigan, United States, 48126

Contacts

Site Public Contact

313-916-3721CTOResearch@hfhs.org

Principal Investigator:

Haythem Y. Ali

Henry Ford Hospital

Recruiting

Detroit, Michigan, United States, 48202

Contacts

Site Public Contact

313-916-3721CTOResearch@hfhs.org

Principal Investigator:

Haythem Y. Ali

Henry Ford Health Saint John Hospital

Recruiting

Detroit, Michigan, United States, 48236

Contacts

Site Public Contact

313-343-3166Kkeenan1@hfhs.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford River District Hospital

Recruiting

East China Township, Michigan, United States, 48054

Contacts

Site Public Contact

313-343-3166kforman1@hfhs.org

Principal Investigator:

Tareq Al baghdadi

Corewell Health Farmington Hills Hospital

Recruiting

Farmington Hills, Michigan, United States, 48336

Contacts

Site Public Contact

248-551-7695

Principal Investigator:

Andrew A. Muskovitz

Cancer Hematology Centers - Flint

Recruiting

Flint, Michigan, United States, 48503

Contacts

Site Public Contact

810-762-8038wstrong@ghci.org

Principal Investigator:

Tareq Al baghdadi

Genesys Hurley Cancer Institute

Recruiting

Flint, Michigan, United States, 48503

Contacts

Site Public Contact

810-762-8038wstrong@ghci.org

Principal Investigator:

Tareq Al baghdadi

Hurley Medical Center

Recruiting

Flint, Michigan, United States, 48503

Contacts

Site Public Contact

810-762-8038wstrong@ghci.org

Principal Investigator:

Tareq Al baghdadi

Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Recruiting

Grand Rapids, Michigan, United States, 49503

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Kathleen Y. Butler

Trinity Health Grand Rapids Hospital

Recruiting

Grand Rapids, Michigan, United States, 49503

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford Saint John Hospital - Academic

Recruiting

Grosse Pointe Woods, Michigan, United States, 48236

Contacts

Site Public Contact

313-343-3166kforman1@hfhs.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford Saint John Hospital - Breast

Recruiting

Grosse Pointe Woods, Michigan, United States, 48236

Contacts

Site Public Contact

313-343-3166karen.forman@ascension.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford Saint John Hospital - Van Elslander

Recruiting

Grosse Pointe Woods, Michigan, United States, 48236

Contacts

Site Public Contact

313-343-3166kforman1@hfhs.org

Principal Investigator:

Tareq Al baghdadi

Allegiance Health

Recruiting

Jackson, Michigan, United States, 49201

Contacts

Site Public Contact

313-916-3721CTOResearch@hfhs.org

Principal Investigator:

Haythem Y. Ali

Bronson Methodist Hospital

Recruiting

Kalamazoo, Michigan, United States, 49007

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Kathleen Y. Butler

West Michigan Cancer Center

Recruiting

Kalamazoo, Michigan, United States, 49007

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Kathleen Y. Butler

Trinity Health Saint Mary Mercy Livonia Hospital

Recruiting

Livonia, Michigan, United States, 48154

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford Saint John Hospital - Macomb Medical

Recruiting

Macomb, Michigan, United States, 48044

Contacts

Site Public Contact

313-343-3166kforman1@hfhs.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford Warren Hospital - Breast Macomb

Recruiting

Macomb, Michigan, United States, 48044

Contacts

Site Public Contact

313-343-3166kforman1@hfhs.org

Principal Investigator:

Tareq Al baghdadi

Trinity Health Muskegon Hospital

Recruiting

Muskegon, Michigan, United States, 49444

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Tareq Al baghdadi

Corewell Health Lakeland Hospitals - Niles Hospital

Recruiting

Niles, Michigan, United States, 49120

Contacts

Site Public Contact

616-391-1230

Principal Investigator:

Kathleen Y. Butler

Cancer and Hematology Centers of Western Michigan - Norton Shores

Recruiting

Norton Shores, Michigan, United States, 49444

Contacts

Site Public Contact

616-391-1230connie.szczepanek@crcwm.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford Medical Center-Columbus

Recruiting

Novi, Michigan, United States, 48377

Contacts

Site Public Contact

313-916-3721CTOResearch@hfhs.org

Principal Investigator:

Haythem Y. Ali

Trinity Health Saint Joseph Mercy Oakland Hospital

Recruiting

Pontiac, Michigan, United States, 48341

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

Corewell Health Reed City Hospital

Recruiting

Reed City, Michigan, United States, 49677

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Kathleen Y. Butler

Corewell Health William Beaumont University Hospital

Recruiting

Royal Oak, Michigan, United States, 48073

Contacts

Site Public Contact

248-551-7695

Principal Investigator:

Andrew A. Muskovitz

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

Recruiting

Saint Joseph, Michigan, United States, 49085

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Kathleen Y. Butler

Corewell Health Lakeland Hospitals - Saint Joseph Hospital

Recruiting

Saint Joseph, Michigan, United States, 49085

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Kathleen Y. Butler

Munson Medical Center

Recruiting

Traverse City, Michigan, United States, 49684

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Kathleen Y. Butler

Corewell Health Beaumont Troy Hospital

Recruiting

Troy, Michigan, United States, 48085

Contacts

Site Public Contact

248-551-7695

Principal Investigator:

Andrew A. Muskovitz

Henry Ford Health Warren Hospital

Recruiting

Warren, Michigan, United States, 48093

Contacts

Site Public Contact

313-343-3166kforman1@hfhs.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford Madison Heights Hospital - Breast

Recruiting

Warren, Michigan, United States, 48093

Contacts

Site Public Contact

313-343-3166kforman1@hfhs.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford Warren Hospital - GLCMS

Recruiting

Warren, Michigan, United States, 48093

Contacts

Site Public Contact

313-343-3166kforman1@hfhs.org

Principal Investigator:

Tareq Al baghdadi

Henry Ford West Bloomfield Hospital

Recruiting

West Bloomfield, Michigan, United States, 48322

Contacts

Site Public Contact

313-916-3721CTOResearch@hfhs.org

Principal Investigator:

Haythem Y. Ali

Henry Ford Wyandotte Hospital

Recruiting

Wyandotte, Michigan, United States, 48192

Contacts

Site Public Contact

nhay@hfhs.org

Principal Investigator:

Haythem Y. Ali

University of Michigan Health - West

Recruiting

Wyoming, Michigan, United States, 49519

Contacts

Site Public Contact

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Kathleen Y. Butler

Huron Gastroenterology PC

Recruiting

Ypsilanti, Michigan, United States, 48106

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Recruiting

Ypsilanti, Michigan, United States, 48197

Contacts

Site Public Contact

734-712-7251MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator:

Tareq Al baghdadi

Minnesota Oncology - Burnsville

Recruiting

Burnsville, Minnesota, United States, 55337

Contacts

Site Public Contact

952-993-1517mmcorc@healthpartners.com

Principal Investigator:

David M. King

Fairview Southdale Hospital

Recruiting

Edina, Minnesota, United States, 55435

Contacts

Site Public Contact

952-993-1517mmcorc@healthpartners.com

Principal Investigator:

David M. King

Minnesota Oncology - Edina

Recruiting

Edina, Minnesota, United States, 55435

Contacts

Site Public Contact

952-993-1517mmcorc@healthpartners.com

Principal Investigator:

David M. King

Abbott-Northwestern Hospital

Recruiting

Minneapolis, Minnesota, United States, 55407

Contacts

Site Public Contact

952-993-1517mmcorc@healthpartners.com

Principal Investigator:

David M. King

Hennepin County Medical Center

Recruiting

Minneapolis, Minnesota, United States, 55415

Contacts

Site Public Contact

952-993-1517mmcorc@healthpartners.com

Principal Investigator:

David M. King

Mayo Clinic in Rochester

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Site Public Contact

855-776-0015

Principal Investigator:

Jacob Orme

Park Nicollet Clinic - Saint Louis Park

Recruiting

Saint Louis Park, Minnesota, United States, 55416

Contacts

Site Public Contact

952-993-1517mmcorc@healthpartners.com

Principal Investigator:

David M. King

Regions Hospital

Recruiting

Saint Paul, Minnesota, United States, 55101

Contacts

Site Public Contact

952-993-1517mmcorc@healthpartners.com

Principal Investigator:

David M. King

United Hospital

Recruiting

Saint Paul, Minnesota, United States, 55102

Contacts

Site Public Contact

952-993-1517mmcorc@healthpartners.com

Principal Investigator:

David M. King

Saint Francis Regional Medical Center

Recruiting

Shakopee, Minnesota, United States, 55379

Contacts

Site Public Contact

952-993-1517mmcorc@healthpartners.com

Principal Investigator:

David M. King

Saint Francis Medical Center

Recruiting

Cape Girardeau, Missouri, United States, 63703

Contacts

Site Public Contact

573-334-2230sfmc@sfmc.net

Principal Investigator:

Bryan A. Faller

Mercy Hospital Joplin

Recruiting

Joplin, Missouri, United States, 64804

Contacts

Site Public Contact

417-556-3074esmeralda.carrillo@mercy.net

Principal Investigator:

Jay W. Carlson

Mercy Hospital Springfield

Recruiting

Springfield, Missouri, United States, 65804

Contacts

Site Public Contact

417-269-4520

Principal Investigator:

Jay W. Carlson

CoxHealth South Hospital

Recruiting

Springfield, Missouri, United States, 65807

Contacts

Site Public Contact

417-269-4520

Principal Investigator:

Jay W. Carlson

Mercy Hospital South

Recruiting

St Louis, Missouri, United States, 63128

Contacts

Site Public Contact

314-525-6042Danielle.Werle@mercy.net

Principal Investigator:

Jay W. Carlson

Saint Vincent Frontier Cancer Center

Recruiting

Billings, Montana, United States, 59102

Contacts

Site Public Contact

800-648-6274

Principal Investigator:

Patrick W. Cobb

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Recruiting

Lebanon, New Hampshire, United States, 03756

Contacts

Site Public Contact

800-639-6918cancer.research.nurse@dartmouth.edu

Principal Investigator:

Kathryn C. Hourdequin

Duke Cancer Center Cary

Recruiting

Cary, North Carolina, United States, 27518

Contacts

Site Public Contact

NCTNStudyTeam@dm.duke.edu

Principal Investigator:

Tucker Coston

Carolinas Medical Center/Levine Cancer Institute

Recruiting

Charlotte, North Carolina, United States, 28203

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Earle F. Burgess

Atrium Health Pineville/LCI-Pineville

Recruiting

Charlotte, North Carolina, United States, 28210

Contacts

Site Public Contact

980-442-2000

Principal Investigator:

Earle F. Burgess

Levine Cancer Institute-SouthPark

Recruiting

Charlotte, North Carolina, United States, 28211

Contacts

Site Public Contact

980-442-2000

Principal Investigator:

Earle F. Burgess

Atrium Health University City/LCI-University

Recruiting

Charlotte, North Carolina, United States, 28262

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Earle F. Burgess

Levine Cancer Institute-Ballantyne

Recruiting

Charlotte, North Carolina, United States, 28277

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Earle F. Burgess

Southeastern Medical Oncology Center-Clinton

Recruiting

Clinton, North Carolina, United States, 28328

Contacts

Site Public Contact

919-587-9084jfields@cancersmoc.com

Principal Investigator:

Samer S. Kasbari

Atrium Health Cabarrus/LCI-Concord

Recruiting

Concord, North Carolina, United States, 28025

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Earle F. Burgess

Duke University Medical Center

Recruiting

Durham, North Carolina, United States, 27710

Contacts

Site Public Contact

888-275-3853

Principal Investigator:

Tucker Coston

Levine Cancer Institute-Gaston

Recruiting

Gastonia, North Carolina, United States, 28054

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Earle F. Burgess

Southeastern Medical Oncology Center-Goldsboro

Recruiting

Goldsboro, North Carolina, United States, 27534

Contacts

Site Public Contact

919-587-9084jfields@cancersmoc.com

Principal Investigator:

Samer S. Kasbari

Southeastern Medical Oncology Center-Jacksonville

Recruiting

Jacksonville, North Carolina, United States, 28546

Contacts

Site Public Contact

910-587-9084jfields@cancersmoc.com

Principal Investigator:

Samer S. Kasbari

FirstHealth of the Carolinas-Moore Regional Hospital

Recruiting

Pinehurst, North Carolina, United States, 28374

Contacts

Site Public Contact

910-715-3500jcwilliams@firsthealth.org

Principal Investigator:

Charles S. Kuzma

Duke Cancer Center Raleigh

Recruiting

Raleigh, North Carolina, United States, 27609

Contacts

Site Public Contact

NCTNStudyTeam@dm.duke.edu

Principal Investigator:

Tucker Coston

Atrium Health Cleveland/LCI-Cleveland

Recruiting

Shelby, North Carolina, United States, 28150

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Earle F. Burgess

Ohio State University Comprehensive Cancer Center

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Site Public Contact

800-293-5066Jamesline@osumc.edu

Principal Investigator:

Bhavana Konda

Cancer Centers of Southwest Oklahoma Research

Recruiting

Lawton, Oklahoma, United States, 73505

Contacts

Site Public Contact

877-231-4440

Principal Investigator:

Sagila George

University of Oklahoma Health Sciences Center

Recruiting

Oklahoma City, Oklahoma, United States, 73104

Contacts

Site Public Contact

405-271-8777ou-clinical-trials@ouhsc.edu

Principal Investigator:

Sagila George

Mercy Hospital Oklahoma City

Recruiting

Oklahoma City, Oklahoma, United States, 73120

Contacts

Site Public Contact

405-752-3402

Principal Investigator:

Jay W. Carlson

Saint Charles Health System

Recruiting

Bend, Oregon, United States, 97701

Contacts

Site Public Contact

541-706-2909nosall@stcharleshealthcare.org

Principal Investigator:

Charles W. Drescher

Providence Portland Medical Center

Recruiting

Portland, Oregon, United States, 97213

Contacts

Site Public Contact

503-215-2614CanRsrchStudies@providence.org

Principal Investigator:

Charles W. Drescher

Providence Saint Vincent Medical Center

Recruiting

Portland, Oregon, United States, 97225

Contacts

Site Public Contact

503-215-2614CanRsrchStudies@providence.org

Principal Investigator:

Charles W. Drescher

WellSpan Medical Oncology and Hematology

Recruiting

Chambersburg, Pennsylvania, United States, 17201

Contacts

Site Public Contact

717-217-6020

Principal Investigator:

Marianne Spengler

Ephrata Cancer Center

Recruiting

Ephrata, Pennsylvania, United States, 17522

Contacts

Site Public Contact

717-721-4840

Principal Investigator:

Marianne Spengler

Adams Cancer Center

Recruiting

Gettysburg, Pennsylvania, United States, 17325

Contacts

Site Public Contact

877-441-7957

Principal Investigator:

Marianne Spengler

WellSpan Medical Oncology and Hematology

Recruiting

Hanover, Pennsylvania, United States, 17331

Contacts

Site Public Contact

717-632-1559

Principal Investigator:

Marianne Spengler

Sechler Family Cancer Center

Recruiting

Lebanon, Pennsylvania, United States, 17042

Contacts

Site Public Contact

717-741-8303doxenberg@wellspan.org

Principal Investigator:

Marianne Spengler

WellSpan Health-York Cancer Center

Recruiting

York, Pennsylvania, United States, 17403

Contacts

Site Public Contact

877-441-7957

Principal Investigator:

Marianne Spengler

Smilow Cancer Hospital Care Center - Westerly

Recruiting

Westerly, Rhode Island, United States, 02891

Contacts

Site Public Contact

203-785-5702canceranswers@yale.edu

Principal Investigator:

Matthew Austin

Levine Cancer Institute-Rock Hill

Recruiting

Rock Hill, South Carolina, United States, 29732

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Earle F. Burgess

Rapid City Regional Hospital

Recruiting

Rapid City, South Dakota, United States, 57701

Contacts

Site Public Contact

605-755-2370research@monument.health

Principal Investigator:

Abdel-Ghani Azzouqa

Vanderbilt University/Ingram Cancer Center

Recruiting

Nashville, Tennessee, United States, 37232

Contacts

Site Public Contact

800-811-8480

Principal Investigator:

Robert A. Ramirez

Parkland Memorial Hospital

Recruiting

Dallas, Texas, United States, 75235

Contacts

Site Public Contact

214-590-5582canceranswerline@UTSouthwestern.edu

Principal Investigator:

Namrata I. Peswani

UT Southwestern Simmons Cancer Center - RedBird

Recruiting

Dallas, Texas, United States, 75237

Contacts

Site Public Contact

214-648-7097canceranswerline@utsouthwestern.edu

Principal Investigator:

Namrata I. Peswani

UT Southwestern/Simmons Cancer Center-Dallas

Recruiting

Dallas, Texas, United States, 75390

Contacts

Site Public Contact

214-648-7097canceranswerline@UTSouthwestern.edu

Principal Investigator:

Namrata I. Peswani

UT Southwestern/Simmons Cancer Center-Fort Worth

Recruiting

Fort Worth, Texas, United States, 76104

Contacts

Site Public Contact

214-648-7097canceranswerline@UTSouthwestern.edu

Principal Investigator:

Namrata I. Peswani

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Site Public Contact

713-798-1354burton@bcm.edu

Principal Investigator:

Tannaz Armaghany

Ben Taub General Hospital

Recruiting

Houston, Texas, United States, 77030

Contacts

Site Public Contact

713-873-2000

Principal Investigator:

Tannaz Armaghany

UT Southwestern Clinical Center at Richardson/Plano

Recruiting

Richardson, Texas, United States, 75080

Contacts

Site Public Contact

972-669-7044Suzanne.cole@utsouthwestern.edu

Principal Investigator:

Namrata I. Peswani

Huntsman Cancer Institute/University of Utah

Recruiting

Salt Lake City, Utah, United States, 84112

Contacts

Site Public Contact

888-424-2100cancerinfo@hci.utah.edu

Principal Investigator:

Heloisa P. Soares

Dartmouth Cancer Center - North

Recruiting

Saint Johnsbury, Vermont, United States, 05819

Contacts

Site Public Contact

800-639-6918cancer.research.nurse@hitchcock.org

Principal Investigator:

Kathryn C. Hourdequin

Fred Hutchinson Cancer Center

Recruiting

Seattle, Washington, United States, 98109

Contacts

Site Public Contact

800-804-8824

Principal Investigator:

David B. Zhen

University of Washington Medical Center - Montlake

Recruiting

Seattle, Washington, United States, 98195

Contacts

Site Public Contact

800-804-8824

Principal Investigator:

David B. Zhen

United Hospital Center

Recruiting

Bridgeport, West Virginia, United States, 26330

Contacts

Site Public Contact

304-293-7374cancertrialsinfo@hsc.wvu.edu

Principal Investigator:

Nour Daboul

West Virginia University Healthcare

Recruiting

Morgantown, West Virginia, United States, 26506

Contacts

Site Public Contact

304-293-7374cancertrialsinfo@hsc.wvu.edu

Principal Investigator:

Nour Daboul

Marshfield Medical Center-EC Cancer Center

Recruiting

Eau Claire, Wisconsin, United States, 54701

Contacts

Site Public Contact

800-782-8581oncology.clinical.trials@marshfieldresearch.org

Principal Investigator:

Dean A. Delmastro

Gundersen Lutheran Medical Center

Recruiting

La Crosse, Wisconsin, United States, 54601

Contacts

Site Public Contact

608-775-2385cancerctr@gundersenhealth.org

Principal Investigator:

David E. Marinier

Marshfield Medical Center-Marshfield

Recruiting

Marshfield, Wisconsin, United States, 54449

Contacts

Site Public Contact

800-782-8581oncology.clinical.trials@marshfieldresearch.org

Principal Investigator:

Dean A. Delmastro

Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Site Public Contact

414-805-3666

Principal Investigator:

Alexandria T. Phan

Marshfield Medical Center - Minocqua

Recruiting

Minocqua, Wisconsin, United States, 54548

Contacts

Site Public Contact

800-782-8581oncology.clinical.trials@marshfieldresearch.org

Principal Investigator:

Dean A. Delmastro

Marshfield Medical Center-Rice Lake

Recruiting

Rice Lake, Wisconsin, United States, 54868

Contacts

Site Public Contact

800-782-8581oncology.clinical.trials@marshfieldresearch.org

Principal Investigator:

Dean A. Delmastro

Marshfield Medical Center-River Region at Stevens Point

Recruiting

Stevens Point, Wisconsin, United States, 54482

Contacts

Site Public Contact

800-782-8581oncology.clinical.trials@marshfieldresearch.org

Principal Investigator:

Dean A. Delmastro

Marshfield Medical Center - Weston

Recruiting

Weston, Wisconsin, United States, 54476

Contacts

Site Public Contact

800-782-8581oncology.clinical.trials@marshfieldresearch.org

Principal Investigator:

Dean A. Delmastro

More Information

Sponsor

National Cancer Institute (NCI)

Last update posted

Sep 30, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-01. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-09-30. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.